Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Autosomal Dominant Polycystic Kidney Disease
NCT05510115Phase 2Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Nov 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in autosomal dominant polycystic kidney disease (ADPKD), sponsored by University of Colorado Denver. Started Nov 2022; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT05510115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05510115.